Categories: News

SMPP Enters into Teaming Agreement with KNDS for KATANA

SMPP, one of India’s leading defence and aerospace companies, has entered into a teaming agreement through its subsidiary SMPP Ammunition with KNDS for the KATANA® range of precision-guided artillery ammunition. The KATANA® is a 155mm precision-guided munition designed to deliver high accuracy and extended range, addressing critical operational needs of modern artillery systems. The agreement was signed on 20th November 2025 at Milipol Exhibition in Paris.

- Advertisement -

 

- Advertisement -

Finalisation of Teaming agreement by SMPP with KNDS

- Advertisement -

 

- Advertisement -

The KATANA® family product includes KATANA® Ballistic Range (BR), Extended Range (ER) and High Precision (HP) with laser seeker ammunition. The KATANA family of ammunition offers a full-calibre Precision Guided Munition with extended capabilities to address armoured threats with decametric-level precision and leverages a hybrid guidance system that combines multi-constellation receiver (GNSS) and an Inertial Measurement Unit (IMU) to ensure accuracy across diverse terrains and combat environments. A future variant is expected to incorporate a semi-active laser seeker to achieve metric-level precision for even more demanding mission profiles. The fire-and-forget capability further enhances its effectiveness in complex operational scenarios, including densely populated urban areas.

- Advertisement -

 

- Advertisement -

Under the teaming agreement, SMPP and KNDS will focus on offering the KATANA® family of ammunition to the Indian Army under the Make in India policy, strengthening India’s capability in advanced artillery ammunition and addressing a key operational requirement for the Indian Armed Forces. This agreement comes at a time when the Indian Army has an extensive and urgent requirement for 155mm artillery systems and ammunition.

- Advertisement -

 

- Advertisement -

SMPP Limited, founded in 1985, is one of India’s leading defence and aerospace manufacturers with a diverse product portfolio that includes personnel protection, platform armouring, medium & large calibre ammunition & unmanned aerial systems (armed/ surveillance) and their respective payloads. The company is actively expanding into new areas critical to India’s defence preparedness. Headquartered in New Delhi, SMPP operates advanced manufacturing facilities in Haryana and Himachal Pradesh.

- Advertisement -

 

- Advertisement -

KNDS Ammo France belongs to KNDS Group which is a European land defence systems leader. As prime contractor and lead system integrator KNDS develop, deliver and sustain state of the art manned and unmanned ‘system-of-systems’, complete mission solutions and its main systems and sub-platforms, including the related ammunitions and services.

- Advertisement -
News Voir

Recent Posts

Xposure Marks 10 Years of Visual Storytelling with Stellar Global Artists

SHARJAH, UAE, Nov. 24, 2025 /PRNewswire/ -- Xposure's International Photography and Film Festival unites 420…

1 hour ago

STAGWELL (STGW) REVEALS NEW SINGAPORE HUB TO POWER AI-DRIVEN GROWTH AND INNOVATION ACROSS APAC

New hub, located at Solaris @ one north, brings together Stagwell's agencies across creativity, media,…

1 hour ago

The Bicester Collection announces the Winners of the Unlock Her Future Prize 2025 – South Asia Edition

Representing Bangladesh, India, Nepal, Pakistan and Bhutan, six bold innovators are advancing inclusive solutions that…

1 hour ago

Terra Madre Asia & Pacific 2025 strengthens communities and advocates for sustainable food systems

BACOLOD CITY, Philippines, Nov. 24, 2025 /PRNewswire/ -- Terra Madre Asia & Pacific 2025 marked…

1 hour ago

Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting

VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the…

3 hours ago

Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

Company Announces Approximately $30 Million in Cash and Short-Term Investments Following Its October 27th Registered…

3 hours ago